Navigation Links
Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million

HAIKOU, China, April 1 /PRNewswire-Asia-FirstCall/ -- Kun Run Biotechnology, Inc., (OTC Bulletin Board: KURU) a leading bio-pharmaceutical company in China that focuses on manufacture and sales of peptides and peptide-based drugs, today announced its financial results for the year ended December 31, 2008.

Revenues for the year ended December 31, 2008 were $11.6 million, an increase of $4.1 million, or 56% over revenues for the same period of 2007.

The gross margin for the year ended December 31, 2008 was 71%, increasing from 58% for the same period of 2007. Selling expenses were $687,949 or 6% of the total sales, for the year ended December 31, 2008, decreasing 51% from $1,416,469 for 2007. The drop was mainly due to the Company's increased marketing budget in 2007 in order to enlarge sales and market share. These expenditures fell back to a more normal level in 2008 as our brands reached a more mature position and extra promotions were not as necessary. Research and development expenses were $271,476 in 2008, equivalent to $276,138 in 2007.

Income from operations increased 262% to $4.8 million in 2008 from $1.7 million for the year ended December 31, 2007. The sharp increase in income from operations was in part due to strong marketing and sales efforts and efficient cost control systems.

Net income increased 378% to approximately $6.0 million for the year ended December 31, 2008. This was an improvement of approximately $4.8 million, from approximately $1.2 million for the same period of 2007. Comprehensive income was $6.8 million compared to $1.4 million in 2007. This increase was in line with the revenue growth and margin improvement and reflects income from disposing property that contributed an additional $2.4 million. Earnings per share for the year ended December 31, 2008 were $0.24 per share (both basic and diluted), compared with $0.05 per share (both basic and diluted) for the same period of 2007. The increase was contributed by increased profitability in 2008. Excluding the effect of a $1.3 million ''Unusual Charge-Make Good Provision'', the actual net income of 2008 was $7.3 million ($0.30 per share), representing a 482% increase over 2007.

At December 31, 2008, the Company had cash and cash equivalents totaling $433,599, working capital was $11.3 million, an improvement of $8.4 million as compared to $2.9 million at December 31, 2007. Net cash provided by operating activities was approximately $5.8 million for the twelve months ended December 31, 2008.

Please refer to documents filed today with the Securities and Exchange Commission for additional information on the results for 2008. Please also visit the Company's web site to learn more about the business .


In commenting on the strong revenue growth, the Company's Chairman, Mr. Xueyun Cui stated, ''TP-5, Kun Run's major product, accounted for 53% of total revenues and contributed $6.2 million of sales in 2008, an increase of 15% over 2007. Since the Company possesses a solution patent for TP-5 pre-filled injections, we enjoyed a stable selling price and strong growth in revenue for TP-5 pre-filled injections, contributing to the total increase in TP-5 as a whole.''

Mr. Xueyun Cui continued, ''Sales of Somatostatin for injection (3mg) accounted for 8% of total sales in 2008, increasing 39% to $961,266 in 2008 from $692,888 in 2007. This was a result of increased recognition of our brands. Thymosin Alpha 1 injection (1.6mg) revenues have grown steadily since it was introduced to the market in 2005, and increased significantly in 2008. A strong market demand for Thymosin Alpha 1 injection (1.6mg) made it the best selling product in 2008 contributing $3.2 million in revenue representing a 247% increase from 2007. Desmopressin acetate injection (DDAVP) also experienced significant sales growth to $1.1 million in 2008, representing a 154% increase.''

Looking toward future revenues, Mr. Xueyun Cui Stated, ''The TP-5 market is mature and is highly competitive while the markets for Somatostatin, DDAVP and Thymosin Alpha 1 are still developing with greater market potential and less pricing pressure. Thus, the Company's product portfolio has broadened from one single flagship product, TP-5, to four peptide products that make and will make major revenue contributions. The Company expects its current product mix to be sustained in the foreseeable future as brand recognition and product efficacy drive product acceptance in the market.''


On September 25, 2008, the company completed a reverse merger with Aspen Racing Stables, Inc., and become a public company in United States. On Nov. 6, 2008, the name of the Company was changed from Aspen Racing Stables to Kun Run Biotechnology, Inc. Also, effectively Nov. 6, 2008, the ticker symbol on the Over-the-Counter Bulletin Board ("OTC BB") changed from "ASRS.OB" to "KURU.OB".

On October 1, 2008, Kun Run's newly completed manufacturing facility obtained the GMP certification and commenced production. The new manufacturing facility is located in Haikou, China, next to Kun Run's existing facility. It is equipped with 6 production lines to produce medicines in six forms, including small volume parenteral solution, prefilled injection, tablets, freeze-dried powder injection, capsules and granules. Combined with the existing 2 freeze-dried powder injection lines, Kun Run now possesses 8 production lines in total that can support our expansion plan and new product launch activities.

About Kun Run Biotechnology, Inc.

Kun Run Biotechnology, Inc., together with its subsidiaries, engages in manufacture and sale of polypeptide medicines. It uses solid phase peptide synthesis (SPPS) and advanced purifying technology to produce various therapeutic polypeptide drugs, of which is "TP-5" most known for efficiently regulating humans' immune systems in order to defend and cure malignant diseases. The company maintains two state-of-art manufacturing plants and possesses one of the largest peptide synthesizing capacities across Asia.

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking statements". Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results are included in the Company's filings, available via the United States Securities and Exchange Commission.

                 Kun Run Biotechnology, Inc. and Subsidiaries
          Consolidated Statements of Income and Comprehensive Income
            For the Twelve Months Ended December 31, 2008 and 2007
                          Expressed in U.S. dollars
                   (Except for share and per share amounts)

                                                     Year ended December 31,
                                                      2008            2007

    Sales revenue                                $11,622,503      $7,471,326
    Cost of sales                                  3,410,891       3,134,608

    Gross profit                                   8,211,612       4,336,718

    Operating expenses
     Administrative expenses                       1,184,864         967,121
     Research and developments costs                 271,476         276,138
     Selling expenses                                687,949       1,416,469
     Unusual charge - make good provision          1,300,000              --
                                                   3,444,289       2,659,728

    Income from operations                         4,767,323       1,676,990
     Government subsidy income                        31,003          22,225
     Interest income                                  50,438           2,741
     Gain on disposal of property, plant
      and equipment                                2,416,110              --
     Other income                                    222,927          47,852
     Finance costs                                  (545,995)       (546,141)

    Income before income taxes and
     minority interest                             6,941,806       1,203,667
    Income taxes                                    (907,439)         56,796
    Minority interest                                (64,658)        (11,095)

    Net Income                                    $5,969,709      $1,249,368

    Other comprehensive income
     Foreign currency translation adjustments        858,953         115,366

    Total comprehensive income                    $6,828,662      $1,364,734

    Earnings per share:
     basic and diluted                                 $0.24           $0.05

    Weighted average number of
     shares outstanding:
     basic and diluted                            24,467,808      24,250,000

                 Kun Run Biotechnology, Inc. and Subsidiaries
                         Consolidated Balance Sheets
                       As Of December 31, 2008 and 2007
                          Expressed in U.S. dollars

                                                        As of December 31,
                                                       2008            2007
     Current assets
      Cash and cash equivalents                     $433,599        $670,919
      Trade receivables, net                       4,732,750       3,460,416
      Bills receivable                               117,360              --
      Other receivables, prepayments and
       deposits                                      985,683       1,418,700
      Receivables from disposal of properties      2,061,793              --
      Inventories                                    689,415         527,308
      Income tax recoverable                              --         196,065
      Amounts due from related companies           5,595,307          68,950
      Deferred taxes                                   8,362          27,220

     Total current assets                         14,624,269       6,369,578
     Intangible assets                               111,004           5,379
     Property, plant and equipment, net            9,685,374       8,851,242
     Land use rights                               3,775,540       3,593,265
     Deposit for acquisition of property,
      plant and equipment                            445,691         943,022

    TOTAL ASSETS                                 $28,641,878     $19,762,486

                                                         As of December 31,
                                                       2008            2007

     Current liabilities
      Trade payables                                $966,937        $572,893
      Other payables and accrued expenses          1,672,500       1,257,918
      Dividend payable to Zhonghe's
       former/existing minority stockholders           7,209          20,863
      Income tax payable                             655,019              --
      Amounts due to related companies                   936         267,616
      Secured borrowings                                  --       1,371,000

     Total current liabilities                     3,302,601       3,490,290
     Deferred taxes                                    8,255              --
     Secured long-term borrowings                  6,528,150       5,792,475

    TOTAL LIABILITIES                              9,839,006       9,282,765


    MINORITY INTEREST                                169,145         103,365

     Preferred stock : par value of $0.001
      per share, authorized 10,000,000
      shares in 2008 and 2007,
      none issued and outstanding                         --              --
     Common stock : par value $0.001 per share
      Authorized 100,000,000 shares in 2008
       and 2007; issued and outstanding
       25,000,000 shares in 2008 and
       24,250,000 shares in 2007                      25,000          24,250
      Additional paid-in capital                   8,969,033       7,541,074
      Statutory and other reserves                 2,820,850       1,725,313
      Accumulated other comprehensive income       1,601,345         742,392
      Retained earnings                            5,217,499         343,327

    TOTAL STOCKHOLDERS' EQUITY                    18,633,727      10,376,356

    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY   $28,641,878     $19,762,486

    For more information, please contact:

     Kunhe Investment management Beijing Co., Ltd,
     Sunne Tang
     Tel:   +86-10-8591-1911

SOURCE Kun Run Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
3. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
4. Letter to Shareholders from the CEO and Chairman of the Board of Yongye Biotechnology, Inc.
5. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 14, 2007; Conference Call set for 1:00 p.m. ET
6. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
7. Bioniche Reports Fiscal 2007 Year-End Results
8. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
9. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
10. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
11. Vasogen to Conduct Year-end 2007 Conference Call
Post Your Comments:
(Date:10/11/2017)... a leading provider of patient support solutions, has announced the ... which will launch this week. The VMS CNEs will address ... enhance the patient care experience by delivering peer-to-peer education programs ... to help women who have been diagnosed and are being ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
Breaking Biology News(10 mins):